Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT07299695Phase 3Recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). Started Jan 2026; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)
Beyond the preview
Go deeper on NCT07299695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299695.